continua IL black FRIDAY al CUBO |15% su tutto con il coupon 15alcubo | SCOPRI di più

Customer care
  • Vicks Flu Triple Action Powder 10 Sachets -47%

Vicks Flu Triple Action Powder 10 Sachets

4.51€ 8.47€
  • Purchase 3 items for 4.42€ each
  • Purchase 4 items for 4.33€ each
  • Purchase 5 items for 4.24€ each

Vicks Flu Triple Action powder

Short-term symptomatic treatment of mild to moderate pain, fever, nasal congestion with expectorant effect in case of a cough, associated with cold, chills and flu.

Composition

One sachet contains: 500 mg paracetamol 200 mg guaifenesin 10 mg phenylephrine hydrochloride Excipients: Sucrose 2000 mg Aspartame 6 mg Sodium 157 mg For a full list of excipients, see section 6.1.

Excipients

Sucrose Citric acid Tartaric acid Sodium cyclamate Sodium citrate Aspartame (E951) Acesulfame potassium (E950) Menthol powder Lemon flavor Lemon juice flavor Quinoline yellow (E104)

Contraindications

Hypersensitivity to paracetamol, guaifenesin, phenylephrine hydrochloride or to any of the excipients. Severe hepatic or renal impairment Hypertension Hyperthyroidism Diabetes Heart disease. Closed-angle glaucoma Porphyria Use in patients who are taking tricyclic antidepressants Use in patients who are taking, or have taken within the previous 2 weeks, monoamine oxidase inhibitors (MAOIs). Use in patients taking beta-blocker drugs Use in patients taking other sympathomimetic drugs Children under 12 years of age.

Dosage

Dissolve the contents of one sachet in a medium-sized cup and add hot, not boiling water (approximately 250 ml). Allow to cool to a drinkable temperature. Adults and children from 12 years of age: one sachet Repeat every four hours as directed, without exceeding four doses (sachets) within 24 hours. Do not administer to children under 12 years of age without medical advice. Do not administer to patients with hepatic or severe renal impairment (see section 4.3). Consult your doctor if symptoms persist for more than 3 days.

Warnings and Precautions

Prolonged use of the product is not recommended. Patients should be advised not to take other products containing paracetamol or containing the same active ingredients as this preparation. Patients should also be advised to avoid concomitant intake of alcohol, other decongestant products, or products against coughs or colds. The doctor or pharmacist is required to verify that preparations containing sympathomimetics are not administered simultaneously through multiple routes, ie orally and topically (nasal, ear and eye preparations). This medicinal product should only be recommended in the presence of all symptoms (pain and / or fever, nasal congestion and bronchial cough). The risks of overdose are greater in patients with non-cirrhotic alcoholic liver disease. Use with caution in patients who are taking digitalis, beta-adrenergic blockers, methyldopa or other antihypertensive agents (see section 4.5). Use with caution in patients with prostatic hypertrophy as they are potentially subject to urinary retention. Products containing sympathomimetics should be used with great care in patients who are taking phenothiazines. Use in patients with Raynaud's phenomenon. Consult your doctor before use in case of persistent or chronic cough such as that manifested by smoking, asthma, chronic bronchitis or emphysema. Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Contains 157 mg of sodium per serving. To be taken into consideration in people with reduced kidney function or who follow a low sodium diet. Contains aspartame (E951). This medicine contains a source of phenylalanine. It can be harmful to you if you have phenylketonuria.

Interactions

The hepatotoxicity of paracetamol can be enhanced by excessive alcohol intake. The absorption rate of paracetamol can be increased with metoclopramide or domperidone and the absorption reduced with cholestyramine. Substances that induce liver microsomal enzymes, such as alcohol, barbiturates, monoamine oxidase inhibitors and tricyclic antidepressants, may increase the hepatotoxicity of paracetamol, particularly following overdose. Isoniazid reduces the elimination of paracetamol, with possible enhancement of its activity and / or toxicity, by inhibiting its metabolism in the liver. Probenecid causes a halving of the elimination of paracetamol, inhibiting its binding with glucuronic acid. A reduction in paracetamol should be considered if probenecid is being taken. Regular use of paracetamol can reduce the metabolism of zidovudine (increasing the risk of neutropenia). Interactions between sympathomimetic amines, such as phenylephrine, and monoamine oxidase inhibitors cause hypertensive effects. Phenylephrine may negatively interact with sympathomimetic agents and may reduce the efficacy of beta-blocking drugs, methyldopa and other antihypertensive drugs (see section 4.4). The conditions in which these drugs are taken are contraindications to the use of the product. The anticoagulant effect of warfarin and other coumarin drugs can be enhanced by regular and prolonged intake of paracetamol, with an increased risk of bleeding; doses taken occasionally have no significant effect. Drug interactions have been reported between paracetamol and several other drugs. These interactions are considered unlikely to be clinically significant in temporary use and according to the suggested dosing regimen. Salicylates / aspirin can prolong the elimination (t ½) of paracetamol. Paracetamol may decrease the bioequivalence of lamotrigine, with possible decrease in its effect, due to a possible increase in its metabolism in the liver. It is possible that digitalis can sensitize the myocardium to effects similar to sympathomimetic substances. Paracetamol can alter the uric acid phosphotungstate test and the blood glucose test.

Side effects

The incidence of undesirable effects is usually classified as follows: Very common (> 10) Common (> 1/100 to <1/10) Uncommon (> 1/1000 to <1/100) Rare (> 1 / 10,000 to <1/1000) Very rare (<1 / 10,000) Not known (incidence cannot be classified from the available data) Cardiac disorders: phenylephrine may be rarely associated with tachycardia (≥1 / 10,000 to ≤ 1 in 1000). Blood and lymphatic system disorders: Very rarely (<1 in 10,000) blood dyscrasias such as thrombocytopenia, agranulocytosis, haemolytic anemia, neutropenia, leukopenia and pancytopenia have been reported following the intake of paracetamol, although there may not be a causal relationship. Nervous system disorders: As with other sympathomimetic amines, insomnia, nervousness, tremor, anxiety, restlessness, confusion, irritability and headache may occur rarely (≥1 / 10,000 to ≤1,000). It is also known that guaifenesin may rarely (≥1 / 10,000 to ≤1 in 1,000) cause headache and dizziness. Gastrointestinal disorders: Anorexia, nausea and vomiting are common with sympathomimetics (≥1 in 100 to ≤1 in 10) and may occur with phenylephrine. Gastrointestinal upset, nausea, vomiting and diarrhea are the most common side effects associated with guaifenesin but occur rarely (≥1 / 10,000 to ≤1 in 1000). Gastrointestinal effects of paracetamol are very rare but cases of acute pancreatitis have been reported following ingestion of higher than normal doses. Renal and urinary disorders: Interstitial nephritis has been reported incidentally after prolonged use of high doses of paracetamol. Skin and subcutaneous tissue disorders: Hypersensitivity, including skin rash, and urticaria (≥1 / 10,000 to ≤1 in 1000) may rarely occur following paracetamol intake. Vascular disorders: Rarely, increased blood pressure associated with headache, vomiting and palpitations (≥1 / 10,000 to ≤1 in 1000) may occur following the intake of phenylephrine. Immune system disorders: Rare cases (≥1 / 10,000 to ≤1 in 1,000) of allergic or hypersensitivity reactions have been reported following the intake of both phenylephrine and paracetamol, including skin rash, urticaria, anaphylaxis and bronchospasm . Hepatobiliary disorders: Rarely (≥ 1 / 10,000 to ≤ 1/1000), abnormal liver function tests (increased liver transaminases).

Pregnancy and breastfeeding

Epidemiological studies on pregnant women have shown the absence of negative effects due to the use of paracetamol in the recommended dosages; however, pregnant patients are required to follow their doctor's advice regarding the use of the drug. Paracetamol is excreted in breast milk, although not in clinically significant amounts. The available published data do not report contraindications regarding breastfeeding. There are limited data on the use of phenylephrine in pregnancy. Vasoconstriction of uterine vessels and decreased uterine blood flow associated with the use of phenylephrine can cause fetal hypoxia. Until further information is available, the use of phenylephrine during pregnancy should be avoided, except in cases where the doctor deems it essential. There are no data available regarding the possible release of phenylephrine in breast milk nor are there any reports regarding the effects of phenylephrine on breastfed infants. Until further data are available, the intake of phenylephrine during breastfeeding should be avoided, except in cases where the physician deems it essential. The safety of guaifenesin in pregnancy and lactation has not yet been fully established. During pregnancy, the product should only be taken in cases where the doctor deems it essential.

Format

Pack of 10 Sachets.

Discover Vicks products

.